Geovax Labs Stock Price, News & Analysis (OTCMKTS:GOVX)

$0.05 0.00 (0.00 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$0.05
Today's Range$0.05 - $0.05
52-Week Range$0.02 - $0.10
Volume868,468 shs
Average Volume597,054 shs
Market Capitalization$4.18 million
P/E Ratio-1.00
Dividend YieldN/A
Beta0.11

About Geovax Labs (OTCMKTS:GOVX)

GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company's platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company's development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company's clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.

Receive GOVX News and Ratings via Email

Sign-up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:GOVX
CUSIPN/A
Phone678-384-7220

Debt

Debt-to-Equity RatioN/A
Current Ratio0.60%
Quick Ratio0.60%

Price-To-Earnings

Trailing P/E Ratio-1
Forward P/E Ratio-1.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$830,000.00
Price / Sales5.05
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-2.50

Profitability

Trailing EPS($0.05)
Net Income$-3,270,000.00
Net Margins-242.06%
Return on EquityN/A
Return on Assets-433.47%

Miscellaneous

Employees11
Outstanding Shares83,910,000

Geovax Labs (OTCMKTS:GOVX) Frequently Asked Questions

What is Geovax Labs' stock symbol?

Geovax Labs trades on the OTCMKTS under the ticker symbol "GOVX."

How were Geovax Labs' earnings last quarter?

Geovax Labs Inc (OTCMKTS:GOVX) issued its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.01). The biotechnology company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.30 million. View Geovax Labs' Earnings History.

When will Geovax Labs make its next earnings announcement?

Geovax Labs is scheduled to release their next quarterly earnings announcement on Friday, March, 23rd 2018. View Earnings Estimates for Geovax Labs.

Who are some of Geovax Labs' key competitors?

Who are Geovax Labs' key executives?

Geovax Labs' management team includes the folowing people:

  • David A. Dodd, Independent Chairman of the Board (Age 65)
  • Robert T. McNally Ph.D., President, Chief Executive Officer, Director (Age 67)
  • Mark W. Reynolds CPA, Chief Financial Officer, Corporate Secretary (Age 53)
  • Harriet Latham Robinson Ph.D., Chief Scientific Officer, Director (Age 77)
  • Randal D. Chase Ph.D., Director (Age 66)
  • Dean G. Kollintzas, Independent Director (Age 41)
  • John N. Spencer Jr., CPA, Independent Director (Age 76)

Who owns Geovax Labs stock?

Geovax Labs' stock is owned by many different of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (9.99%), SABBY MANAGEMENT, LLC (9.99%), EMORY UNIVERSITY (5.50%) and EMORY UNIVERSITY (5.50%). View Institutional Ownership Trends for Geovax Labs.

How do I buy Geovax Labs stock?

Shares of Geovax Labs can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geovax Labs' stock price today?

One share of Geovax Labs stock can currently be purchased for approximately $0.05.

How big of a company is Geovax Labs?

Geovax Labs has a market capitalization of $4.18 million and generates $830,000.00 in revenue each year. The biotechnology company earns $-3,270,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Geovax Labs employs 11 workers across the globe.

How can I contact Geovax Labs?

Geovax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The biotechnology company can be reached via phone at 678-384-7220 or via email at [email protected]


MarketBeat Community Rating for Geovax Labs (GOVX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  46
MarketBeat's community ratings are surveys of what our community members think about Geovax Labs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Geovax Labs (OTCMKTS:GOVX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Geovax Labs (OTCMKTS:GOVX) Earnings History and Estimates Chart

Earnings by Quarter for Geovax Labs (OTCMKTS:GOVX)

Geovax Labs (OTCMKTS GOVX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/23/2018        
11/9/2017Q3 2017($0.01)($0.01)$0.30 million$0.25 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.01)($0.01)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.01)ViewN/AView Earnings Details
3/24/2017Q4 2016($0.01)($0.02)ViewN/AView Earnings Details
11/11/2016Q3 2016($0.02)($0.01)ViewN/AView Earnings Details
8/5/2016Q2 2016($0.02)($0.02)ViewN/AView Earnings Details
5/4/2016Q1 2016($0.04)ViewN/AView Earnings Details
3/16/2016Q4 2015($0.02)($0.02)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.02)($0.02)ViewN/AView Earnings Details
8/4/2015Q2 2015($0.03)($0.02)ViewN/AView Earnings Details
5/13/2015Q1 2015($0.03)($0.02)ViewN/AView Earnings Details
3/20/2015Q4 2014($0.03)($0.03)ViewN/AView Earnings Details
11/19/2014($0.03)($0.02)ViewN/AView Earnings Details
8/22/2014($0.03)($0.03)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.03)($0.03)ViewN/AView Earnings Details
5/2/2014($0.03)($0.02)ViewN/AView Earnings Details
3/5/2014Q4 2013($0.04)($0.04)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.05)($0.01)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.04)($0.02)ViewN/AView Earnings Details
5/2/2013Q1 2013($0.04)($0.03)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.01)($0.03)ViewN/AView Earnings Details
11/14/2012Q3 2012($0.02)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.03)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.04)ViewN/AView Earnings Details
3/28/2012Q4 2011($0.07)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.02)ViewN/AView Earnings Details
8/12/2011Q2 2011($0.01)ViewN/AView Earnings Details
4/27/2011Q1 2011($0.04)ViewN/AView Earnings Details
2/25/2011Q4 2010($0.03)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.04)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.06)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.04)ViewN/AView Earnings Details
3/1/2010Q4 2009($0.05)ViewN/AView Earnings Details
8/7/2009Q2 2009($0.20)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.15)ViewN/AView Earnings Details
3/12/2009Q4 2008($0.05)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.10)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.20)ViewN/AView Earnings Details
3/14/2008Q4 2007($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Geovax Labs (OTCMKTS:GOVX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.04 EPS
Next Year EPS Consensus Estimate: $-0.07 EPS

Dividends

Dividend History for Geovax Labs (OTCMKTS:GOVX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Geovax Labs (OTCMKTS GOVX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Insider Trades by Quarter for Geovax Labs (OTCMKTS:GOVX)
Institutional Ownership by Quarter for Geovax Labs (OTCMKTS:GOVX)

Geovax Labs (OTCMKTS GOVX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/5/2015Randal D ChaseDirectorBuy10,000$0.19$1,900.00View SEC Filing  
4/23/2015Mark ReynoldsCFOBuy30,000$0.17$5,100.00View SEC Filing  
4/20/2015Randal D ChaseDirectorBuy30,000$0.17$5,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Geovax Labs (OTCMKTS GOVX) News Headlines

Source:
DateHeadline
GeoVax Publishes Ebola Vaccine Study Results in Nature’s Scientific ReportsGeoVax Publishes Ebola Vaccine Study Results in Nature’s Scientific Reports
finance.yahoo.com - January 16 at 9:21 AM
Geovax Labs, Inc. (GOVX) Announces Collaboration with Vaxeal on Cancer Immunotherapy ProgramGeovax Labs, Inc. (GOVX) Announces Collaboration with Vaxeal on Cancer Immunotherapy Program
www.streetinsider.com - January 4 at 9:16 AM
GeoVax and Vaxeal to Collaborate on Cancer Immunotherapy ProgramGeoVax and Vaxeal to Collaborate on Cancer Immunotherapy Program
finance.yahoo.com - January 3 at 5:35 PM
GeoVax to Present During China Showcase at Biotech Showcase 2018GeoVax to Present During China Showcase at Biotech Showcase 2018
finance.yahoo.com - January 2 at 7:00 PM
GeoVax to Conduct Investor and Partnering Meetings During J.P. Morgan 36th Annual Healthcare ConferenceGeoVax to Conduct Investor and Partnering Meetings During J.P. Morgan 36th Annual Healthcare Conference
finance.yahoo.com - December 18 at 9:29 AM
GeoVax Labs Inc. (GOVX) Downgraded by ValuEngineGeoVax Labs Inc. (GOVX) Downgraded by ValuEngine
www.americanbankingnews.com - November 25 at 6:06 AM
GeoVax HIV Clinical Trials UpdateGeoVax HIV Clinical Trials Update
finance.yahoo.com - November 16 at 2:50 PM
GOVX: Continues to move forward with its Multiple Vaccine ProgramsGOVX: Continues to move forward with its Multiple Vaccine Programs
finance.yahoo.com - November 13 at 7:18 PM
GeoVax to Present at the Third International Conference on Vaccines Research and DevelopmentGeoVax to Present at the Third International Conference on Vaccines Research and Development
finance.yahoo.com - November 13 at 9:28 AM
GeoVax Labs Inc. (GOVX) Upgraded to "Sell" at ValuEngineGeoVax Labs Inc. (GOVX) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - November 11 at 6:18 PM
GeoVax Publishes Zika Vaccine Study Results in Natures Scientific ReportsGeoVax Publishes Zika Vaccine Study Results in Nature's Scientific Reports
finance.yahoo.com - November 8 at 8:10 AM
GeoVax Reports Significant Advance in HIV Vaccine DevelopmentGeoVax Reports Significant Advance in HIV Vaccine Development
finance.yahoo.com - October 12 at 2:57 AM
GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine CongressGeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress
finance.yahoo.com - October 9 at 7:20 PM
GeoVax to Present at International Society for Vaccines Annual CongressGeoVax to Present at International Society for Vaccines Annual Congress
finance.yahoo.com - October 2 at 1:54 PM
GeoVax Provides Update on its Zika Vaccine DevelopmentGeoVax Provides Update on its Zika Vaccine Development
finance.yahoo.com - September 18 at 6:41 PM
GeoVax Presents Preliminary Data for Cancer VaccineGeoVax Presents Preliminary Data for Cancer Vaccine
finance.yahoo.com - August 30 at 4:32 PM
GeoVax Presents Zika Vaccine Data at Scientific ConferenceGeoVax Presents Zika Vaccine Data at Scientific Conference
finance.yahoo.com - August 30 at 4:32 PM
GeoVax to Present at Upcoming Immuno-Oncology ConferenceGeoVax to Present at Upcoming Immuno-Oncology Conference
finance.yahoo.com - August 22 at 7:42 PM
GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever VaccineGeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine
finance.yahoo.com - July 24 at 9:07 PM
GeoVax Reports Promising Results for Lassa Fever VaccineGeoVax Reports Promising Results for Lassa Fever Vaccine
finance.yahoo.com - July 10 at 7:06 PM
Atlanta biotech firm GeoVax raises $1 million in stock saleAtlanta biotech firm GeoVax raises $1 million in stock sale
www.bizjournals.com - May 9 at 12:39 PM
BRIEF-GeoVax announces initiation of HIV Human Clinical TrialBRIEF-GeoVax announces initiation of HIV Human Clinical Trial
www.reuters.com - January 23 at 11:20 AM
Zika vaccine developer names new chief scientific officerZika vaccine developer names new chief scientific officer
www.bizjournals.com - January 3 at 11:57 AM
GEOVAX LABS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission ofGEOVAX LABS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of
biz.yahoo.com - June 16 at 10:10 AM
GeoVax Recognizes National Black HIV/AIDS Awareness Day / Bringing Attention to Minority Health Disparities in HIV/AIDS and the Need for a VaccineGeoVax Recognizes National Black HIV/AIDS Awareness Day / Bringing Attention to Minority Health Disparities in HIV/AIDS and the Need for a Vaccine
www.finanznachrichten.de - February 5 at 2:10 PM
Indian Pharma Files For Patent For First Zika VaccineIndian Pharma Files For Patent For First Zika Vaccine
www.nasdaq.com - February 3 at 1:38 PM

SEC Filings

Geovax Labs (OTCMKTS:GOVX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Geovax Labs (OTCMKTS:GOVX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Geovax Labs (OTCMKTS GOVX) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.